Abstract
The aim of the study was to identify a predictive marker for the virological response in hepatitis C virus 1b (HCV-1b)-infected patients treated with pegylated interferon plus ribavirin therapy. A total of 139 patients with chronic hepatitis C who received therapy for 48 weeks were enrolled. The secondary structure of the 120 residues of the amino-terminal HCV-1b non-structural region 3 (NS3) deduced from the amino acid sequence was classified into two major groups: A and B. The association between HCV NS3 protein polymorphism and virological response was analyzed in patients infected with group A (n = 28) and B (n = 40) isolates who had good adherence to both pegylated interferon and ribavirin administration (>95% of the scheduled dosage) for 48 weeks. A sustained virological response (SVR) representing successful HCV eradication occurred in 33 (49%) in the 68 patients. Of the 28 patients infected with the group A isolate, 18 (64%) were SVR, whereas of the 40 patients infected with the group B isolate only 15 (38%) were SVR. The proportion of virological responses differed significantly between the two groups (P < 0.05). These results suggest that polymorphism in the secondary structure of the HCV-1b NS3 amino-terminal region influences the virological response to pegylated interferon plus ribavirin therapy, and that virus grouping based on this polymorphism can contribute to prediction of the outcome of this therapy.
(c) 2010 Wiley-Liss, Inc.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antiviral Agents / therapeutic use*
-
Female
-
Hepacivirus / drug effects*
-
Hepacivirus / genetics
-
Hepacivirus / isolation & purification
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / virology*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Male
-
Middle Aged
-
Molecular Sequence Data
-
Polyethylene Glycols / therapeutic use*
-
Polymorphism, Genetic
-
Protein Structure, Secondary
-
RNA, Viral / genetics
-
Recombinant Proteins
-
Ribavirin / therapeutic use*
-
Sequence Analysis, DNA
-
Treatment Outcome
-
Viral Load
-
Viral Nonstructural Proteins / chemistry*
-
Viral Nonstructural Proteins / genetics
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
NS3 protein, hepatitis C virus
-
RNA, Viral
-
Recombinant Proteins
-
Viral Nonstructural Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2b
Associated data
-
GENBANK/AB548070
-
GENBANK/AB548071
-
GENBANK/AB548072
-
GENBANK/AB548073
-
GENBANK/AB548074
-
GENBANK/AB548075
-
GENBANK/AB548076
-
GENBANK/AB548077
-
GENBANK/AB548078
-
GENBANK/AB548079
-
GENBANK/AB548080
-
GENBANK/AB548081
-
GENBANK/AB548082
-
GENBANK/AB548083
-
GENBANK/AB548084
-
GENBANK/AB548085
-
GENBANK/AB548086
-
GENBANK/AB548087
-
GENBANK/AB548088
-
GENBANK/AB548089
-
GENBANK/AB548090
-
GENBANK/AB548091
-
GENBANK/AB548092
-
GENBANK/AB548093
-
GENBANK/AB548094
-
GENBANK/AB548095
-
GENBANK/AB548096
-
GENBANK/AB548097
-
GENBANK/AB548098
-
GENBANK/AB548099
-
GENBANK/AB548100
-
GENBANK/AB548101
-
GENBANK/AB548102
-
GENBANK/AB548103
-
GENBANK/AB548104
-
GENBANK/AB548105
-
GENBANK/AB548106
-
GENBANK/AB548107
-
GENBANK/AB548108
-
GENBANK/AB548109
-
GENBANK/AB548110
-
GENBANK/AB548111
-
GENBANK/AB548112
-
GENBANK/AB548113
-
GENBANK/AB548114
-
GENBANK/AB548115
-
GENBANK/AB548116
-
GENBANK/AB548117
-
GENBANK/AB548118
-
GENBANK/AB548119
-
GENBANK/AB548120
-
GENBANK/AB548121
-
GENBANK/AB548122
-
GENBANK/AB548123
-
GENBANK/AB548124
-
GENBANK/AB548125
-
GENBANK/AB548126
-
GENBANK/AB548127
-
GENBANK/AB548128
-
GENBANK/AB548129
-
GENBANK/AB548130
-
GENBANK/AB548131
-
GENBANK/AB548132
-
GENBANK/AB548133
-
GENBANK/AB548134
-
GENBANK/AB548135
-
GENBANK/AB548136
-
GENBANK/AB548137